Disturbance of activity and attention. Disturbance of activity and attention
Conditions
Interventions
Intervention 1: Tablet Agomelatine 25 mg/day as intervention group for 6 weeks. Intervention 2: Tablet Ritalin 20-30 mg/kg/day for 6 weeks as control group.
Treatment - Drugs
Tablet Agomelatine 25 mg/day as intervention group for 6 weeks
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
6 Years to 17 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: diagnosis of ADHD based on DSM-IV and age between 6-17 years old. Exclusion criteria: receiving of any psychotropics drugs during past two weeks; presence of any psychiatric disorders or mental retardation (I.Q. <70) except for ODD; history of allergy to Agomelatine or Ritaline; presence of any medical problem including cardiovascular diseases; presence of uncontrolled seizures; systolic blood pressure more than 120 mm Hg; resting pulse rate less than 60/minute or more than 115/minute; liver enzymes more than normal range.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of ADHD. Timepoint: Week 0 (before treatment) and Weeks 2, 4 and 6 after treatment. Method of measurement: Teacher and Parent ADHD Rating Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactProf. Shahin Akhondzadeh
Tehran University of Medical Sciences
Outcome results
None listed